CA3132400C - Compositions and methods to treat gastrointestinal diseases and disorders - Google Patents

Compositions and methods to treat gastrointestinal diseases and disorders

Info

Publication number
CA3132400C
CA3132400C CA3132400A CA3132400A CA3132400C CA 3132400 C CA3132400 C CA 3132400C CA 3132400 A CA3132400 A CA 3132400A CA 3132400 A CA3132400 A CA 3132400A CA 3132400 C CA3132400 C CA 3132400C
Authority
CA
Canada
Prior art keywords
rifaximin
mucolytic agent
nac
combination
various embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3132400A
Other languages
English (en)
French (fr)
Other versions
CA3132400A1 (en
Inventor
Mark Pimentel
Gabriela Guimaraes Sousa Leite
Ruchi Mathur
Ali REZAIE
Walter Morales
Stacy Weitsman
Original Assignee
Cedars-Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars-Sinai Medical Center filed Critical Cedars-Sinai Medical Center
Priority to CA3293273A priority Critical patent/CA3293273A1/en
Publication of CA3132400A1 publication Critical patent/CA3132400A1/en
Application granted granted Critical
Publication of CA3132400C publication Critical patent/CA3132400C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3132400A 2019-03-18 2020-03-18 Compositions and methods to treat gastrointestinal diseases and disorders Active CA3132400C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3293273A CA3293273A1 (en) 2019-03-18 2020-03-18 Compositions and methods to treat gastrointestinal diseases and disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819986P 2019-03-18 2019-03-18
US62/819,986 2019-03-18
PCT/US2020/023396 WO2020191076A1 (en) 2019-03-18 2020-03-18 Compositions and methods to treat gastrointestinal diseases and disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3293273A Division CA3293273A1 (en) 2019-03-18 2020-03-18 Compositions and methods to treat gastrointestinal diseases and disorders

Publications (2)

Publication Number Publication Date
CA3132400A1 CA3132400A1 (en) 2020-09-24
CA3132400C true CA3132400C (en) 2026-05-12

Family

ID=72520533

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3132400A Active CA3132400C (en) 2019-03-18 2020-03-18 Compositions and methods to treat gastrointestinal diseases and disorders
CA3293273A Pending CA3293273A1 (en) 2019-03-18 2020-03-18 Compositions and methods to treat gastrointestinal diseases and disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3293273A Pending CA3293273A1 (en) 2019-03-18 2020-03-18 Compositions and methods to treat gastrointestinal diseases and disorders

Country Status (7)

Country Link
US (1) US12642793B2 (cg-RX-API-DMAC10.html)
EP (1) EP3941461A4 (cg-RX-API-DMAC10.html)
JP (1) JP2022526495A (cg-RX-API-DMAC10.html)
CN (1) CN113645968A (cg-RX-API-DMAC10.html)
AU (2) AU2020240069B2 (cg-RX-API-DMAC10.html)
CA (2) CA3132400C (cg-RX-API-DMAC10.html)
WO (1) WO2020191076A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3132400C (en) 2019-03-18 2026-05-12 Cedars-Sinai Medical Center Compositions and methods to treat gastrointestinal diseases and disorders
EP4510915A4 (en) * 2022-04-20 2026-01-21 Cedars Sinai Medical Center METHODS FOR DIAGNOSING IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) AND SELECTING AN ANTI-IBS-D TREATMENT
JP2025516807A (ja) * 2022-05-19 2025-05-30 シーダーズ－サイナイ メディカル センター リファキシミンとｎ－アセチルシステインの製剤

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1235529A (en) * 1968-12-02 1971-06-16 Calbiochem Composition for mucolysis
ES392136A1 (es) 1971-06-11 1973-03-01 Espanola Prod Quimicos Un procedimiento de obtencion de una sal de doxiciclina.
IT1134458B (it) 1980-11-26 1986-08-13 Real Sas Di Alberto Reiner Derivato della n-acetil-cisteina ad attivita' terapeutica,procedimento per la sua preparazione e relative composizioni farmaceutiche
IT1141959B (it) 1981-01-27 1986-10-08 Istituto Biochimico Italiano Nuovi sali ad attivita' antibiotica e mucolitica
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
TWI236905B (en) * 1997-10-28 2005-08-01 Jens Ponikau Pharmaceutical composition for treating and preventing inflammation of mucosal tissue
WO2000023081A1 (en) 1998-10-20 2000-04-27 Lauteral Limited Derivatives of erythromycin, clarithromycin, roxithromycin or azithromycin with antibiotic and mucolytic activity
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20060264409A1 (en) 2004-01-20 2006-11-23 Harty Richard F Compositions and methods of treatment for inflammatory diseases
US20080194456A1 (en) * 2004-04-09 2008-08-14 The General Hospital Corporation Compositions And Methods Related To An Intestinal Inflammation And Uses Therefor
CN101039701A (zh) * 2004-08-26 2007-09-19 尼古拉斯皮拉马尔印度有限公司 含有生物可裂解二硫化物连接物的前药和共药
WO2008002971A2 (en) * 2006-06-29 2008-01-03 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
MXPA06014635A (es) 2006-12-14 2008-11-26 Senosiain S A De C V Lab Composicion farmaceutica que contiene una combinacion de antibiotico y mucolitico y su uso.
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
GB0823472D0 (en) * 2008-12-23 2009-01-28 Photocure Asa Product
US9408393B2 (en) 2010-02-03 2016-08-09 Microbion Corporation Bismuth-thiols as antiseptics for agricultural, industrial and other uses
GB0905451D0 (en) 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
AU2011212941B2 (en) * 2010-02-03 2016-03-03 Microbion Corporation Bismuth-thiols as antiseptics for biomedical uses, including treatment of bacterial biofilms and other uses
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
BR112015004165A2 (pt) 2012-08-29 2017-07-04 Salix Pharmaceuticals Inc métodos e composições laxantes para o tratamento de constipação e condições e doenças gastrointestinais relacionadas
WO2014036445A2 (en) * 2012-08-31 2014-03-06 Johnson Michael R Novel mucolytic agents
CN104812369B (zh) 2012-10-26 2017-11-24 心悦生医股份有限公司 壳核粒子与其制造方法以及含有壳核粒子的组合物
CA3153463A1 (en) 2012-10-29 2014-05-08 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
EP2991649B1 (en) 2013-04-30 2020-06-03 Thomas Julius Borody Compositions for treating obsessive-compulsive disorder
ITMI20130874A1 (it) * 2013-05-29 2014-11-30 Zambon Spa Compresse deglutibili di n-acetilcisteina
US20160158262A1 (en) * 2013-07-26 2016-06-09 Cedars-Sinai Medical Center Methods of treating irritable bowel syndrome
MX381919B (es) 2014-06-30 2025-03-13 Salix Pharmaceuticals Inc Métodos para repetir tratamiento de síndrome del intestino irritable (ibs).
US10953070B2 (en) * 2014-07-25 2021-03-23 Agency For Science, Technology And Research Antibiotic compositions for treating bacterial infections
RU2737891C2 (ru) * 2015-04-30 2020-12-04 Пробиотикал С.П.А Применение антибиотиков со специфичными терапевтическими активностями в комбинации с одновременным применением лактобацилл и/или бифидобактерий с непередающейся устойчивостью к антибиотикам, имеющих такое же терапевтическое показание
WO2017210428A1 (en) 2016-06-01 2017-12-07 Crestovo Llc Compositions and methods for treating inflammatory bowel diseases (ibds) and other disorders
GB201621447D0 (en) 2016-12-16 2017-02-01 Novabiotics Ltd Use
CA3055311A1 (en) * 2017-02-07 2018-08-16 Stc.Unm Isotope enhanced ambroxol for long lasting autophagy induction
WO2018174839A1 (en) 2017-03-18 2018-09-27 Nguyen Mark Quang Cysteine, n-acetylcysteine and penicillamine prodrugs, pharmaceutical compositions thereof, and methods of use
JP2020513041A (ja) 2017-04-10 2020-04-30 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ 病原体の阻害および／または粘液の改変のための化合物、組成物、および方法
KR20200060424A (ko) 2017-09-20 2020-05-29 아토픽 메디컬, 엘엘씨. 호흡기 질환 및 점막 염증의 치료 및 개선을 위한 조성물 및 방법
US20220186281A1 (en) 2019-01-30 2022-06-16 Cedars-Sinai Medical Center Method for processing and analysis of viscous liquid biological samples
CA3132400C (en) 2019-03-18 2026-05-12 Cedars-Sinai Medical Center Compositions and methods to treat gastrointestinal diseases and disorders
JP2025516807A (ja) 2022-05-19 2025-05-30 シーダーズ－サイナイ メディカル センター リファキシミンとｎ－アセチルシステインの製剤

Also Published As

Publication number Publication date
CA3132400A1 (en) 2020-09-24
EP3941461A4 (en) 2022-12-14
AU2025271108A1 (en) 2025-12-18
JP2022526495A (ja) 2022-05-25
US20230038019A1 (en) 2023-02-09
US12642793B2 (en) 2026-06-02
AU2020240069B2 (en) 2025-08-28
EP3941461A1 (en) 2022-01-26
CA3293273A1 (en) 2026-03-02
WO2020191076A1 (en) 2020-09-24
CN113645968A (zh) 2021-11-12
AU2020240069A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
AU2025271108A1 (en) Compositions and methods to treat gastrointestinal diseases and disorders
US20040067223A1 (en) Probiotic compositions for the treatment of inflammatory bowel disease
US20090252708A1 (en) Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof
US11154589B2 (en) Antimicrobial composition combinations comprising star shaped peptide polymers
AU2010213773B2 (en) Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
CA2702221A1 (en) Methods and kits for the treatment of diverticular conditions
US9913904B2 (en) Use of an agent consisting of antibodies and/or insulin-like growth factor antagonists
EP2987503A1 (en) Methods and reagents for prevention and/or treatment of infection
García-Morán et al. Myopericarditis and mitral insufficiency associated with ulcerative colitis treated with mesalazine
US20190224150A1 (en) Method of treatment and prevention of bacterial vaginosis
HK40064209A (en) Compositions and methods to treat gastrointestinal diseases and disorders
US20140099328A1 (en) Antibody product comprising n specific antibodies
CN102470141A (zh) 作为用于抗微生物肽产生能力的滋补剂的甘草酸
JP2023517579A (ja) 呼吸器系の病変の治療のための組成物
KR20230041964A (ko) 박테리아 균주를 포함하는 조성물 및 눈 질환과 병변을 치료하기 위한 그 용도
RU2297835C1 (ru) Препарат для лечения неинфекционных воспалительных болезней кишечника
RU2810419C1 (ru) Способ лечения хронического пародонтита
JP7705844B2 (ja) クロストリディオイデス ディフィシル菌増殖抑制剤
RU2108106C1 (ru) Пектиновый препарат для лечения диарейных инфекций человека и животных
US20080159987A1 (en) Use of Rifaximin for the Treatment of Restless Legs Syndrome
RU1790409C (ru) Способ лечени гнойно-воспалительного процесса
WO2024028863A1 (en) Therapeutic effect of molecules derived from probiotic milk-based fermentation microbial consortium ("kefir") on wounds healing
Browning et al. The chemotherapy of pyogenic infections with special reference to the antiseptic properties of acridine compounds
JPS6388132A (ja) 胃潰瘍治療薬
Sood Therapeutic Strategies for Uterine Infections in Cows

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220926

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20240926

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241217

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241217

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250310

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250310

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250310

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250718

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250718

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20250806

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20251118

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260306

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260306

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260402

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260402

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20260507

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20260512